INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending granting marketing authorisation for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) in adults.1 In September, the U.S. Food and Drug Administration (FDA) approved nintedanib as the first and only medicine to slow the rate of decline in pulmonary function in adults living with SSc-ILD. Regulatory approvals for the treatment of patients living with SSc-ILD have also been granted in other countries including Canada, Japan and Brazil.
Systemic sclerosis (SSc), also known as scleroderma, is a disfiguring, disabling and potentially fatal rare autoimmune disease.3,4,5 It causes scarring (fibrosis) of various organs, including the lungs, heart, digestive tract and kidneys and can have life-threatening complications. When SSc affects the lungs, it can cause interstitial lung disease (ILD), known as SSc-ILD.2,6 ILD is the leading cause of mortality in SSc, accounting for almost 35% of SSc-related deaths.7
“SSc-ILD is a life-changing disease. Once fibrosis of the lungs occurs it cannot be reversed, and this can have a devastating impact on a patient’s life and daily activities” said Peter Fang, Senior Vice President and Head of Therapeutic Area Inflammation at Boehringer Ingelheim. “Striving to improve the lives of people living with pulmonary fibrosis, we are pleased with the Committee’s positive opinion, which represents an important step forward in helping to slow down the progression of this rare and life-changing disease.”
The positive opinion was based on the results of the SENSCIS® trial, a phase III, double-blind, placebo-controlled trial conducted to investigate the efficacy and safety of nintedanib in patients with ILD-associated systemic sclerosis (SSc-ILD).2 The primary endpoint was the annual rate of decline in Forced Vital Capacity (FVC) assessed over a 52-week period. Patients remained on the study treatment for at least 52 weeks of treatment or for a maximum of 100 weeks of treatment. Results showed nintedanib slowed the loss of pulmonary function by 44% (41mL/year) relative to placebo, as measured in FVC over 52 weeks.2 The adverse-event profile of nintedanib was similar to that observed in patients with idiopathic pulmonary fibrosis, with the most common adverse event being diarrhoea.2
~ENDS~
冠科生物新发表的论文详细介绍了体外3D
“海河锦鲤,跃动津城”全国创意作品征集大赛
科广新纪元——3.0 RPA时代瞩目到来,小科机器
明天,全国降半旗!
致最美的逆行者丨您温暖我们,我们感谢您!
沙特阿拉伯埃尔奥拉皇家委员会宣布,两只阿拉
喜善汇文艺社 中国侯派艺术传统艺术表演团队
C3.ai、微软和知名大学成立C3.ai数字化转型研究
ExaGrid在Storage Awards
Vifor Pharma to spearhead de
上饶灵山景区索道年检完毕,今日开放!
这七大领域重大风险如何化解?习近平提出明确
传统山水画家刘连君作品欣赏
Gigaphoton在中国成立新公司
Corpay将成为太阳剧团的全球外汇合作伙伴
超值!江西灵山参赛福利已到位
一场沈阳豪宅与藏品级豪车的携手,缔造圈层交
The LYCRA Company推出一年一度的秋季牛仔
精致主义生活极致到什么程度?看东原“印”系
LRN Corporation已完成对汤森路透旗下
Andersen Global拓展北非业务
EKF Life Sciences 携手ABEC
Hayashi Telempu Makes
肯德基首款和牛汉堡亮相